In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: PennyMac's current price exceeds its PERT-weighted fair value by 10.9%, with conflicting signals from valuation methods ranging widely from negative DCF to strong EV/EBITDA and analyst targets. Financial health scores are poor, especially liquidity and leverage, indicating elevated operational risks. Monte Carlo analysis shows high volatility and significant upside potential, though median value remains moderately below market price.